Tag Archives: Hemispherx

CFSAC Comments August 2015: Ampligen Price Increase on Shaky Ground

I looked into the Ampligen issue–the exorbitant 267% price increase by Hemispherx–some more. Here is one thing that patients who are currently enrolled in the trial can do. They can contact Schulman Associates, the Institutional Review Board (IRB) for this … Continue reading

Posted in Uncategorized | Tagged , , , , , , , , , , , , , | 42 Comments

267% Price Increase for Ampligen

[Please see here for my follow-up letter to Dr. Woodcock.] I just sent the following message regarding Hemispherx’s extraordinary 267% price increase for Ampligen to Dr. Janet Woodcock, the FDA’s Director of the Center for Drug Evaluation and Research: Dear Dr. … Continue reading

Posted in Uncategorized | Tagged , , , , , , , , , , | 31 Comments

Thoughts on the May 2013 CFSAC Meeting

I’ll have a lot more thoughts about this week’s CFSAC meeting in Washington, D.C. once I get a chance to watch the videos because I wasn’t well enough to take notes or attend (or closely follow) the entire meeting. But … Continue reading

Posted in Uncategorized | Tagged , , , , , , , , , , , , , , , , , , , , , , | 38 Comments

“I have a plane to catch”

I am still working through all the emotions triggered by the highly anticipated December 20, 2012 FDA Arthritis Advisory Committee meeting about the approval of Ampligen, an immune-modulatory drug that has been very successful in treating a sub-group of myalgic … Continue reading

Posted in Uncategorized | Tagged , , , , , , , , , , , , , , , , , | 66 Comments